Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04980222 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

A Phase 2 study of Lymphoma, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 2
Development phase
46
Enrollment target
18
Study locations

NCT04980222 is a Phase 2 study of Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 46 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 18 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04980222, a Phase 2 study of Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
18
Study locations

Study Summary

This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffuse large B-cell lymphoma (DLBCL), as the first line of treatment.

Conditions Studied

Lymphoma

Interventions

  • DRUG Glofitamab
  • DRUG Doxorubicin
  • DRUG Vincristine
  • DRUG Prednisone
  • DRUG Tocilizumab

Study Locations (18)

Other

  • Aarhus Universitetshospital Skejby - Aarhus N
  • Hopital Henri Mondor - Créteil
  • Centre Henri Becquerel - Rouen
  • Universitair Medisch Centrum Groningen - Groningen
  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii - Gdansk
  • Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku - Wroclaw
  • Hospital Clinic i Provincial de Barcelona - Barcelona
  • Hospital General Universitario Gregorio Marañon - Madrid
  • Hospital Univ. 12 de Octubre; Servicio de Hematologia - Madrid
  • Hospital Clinico Universitario de Salamanca - Salamanca

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Stanford Cancer Center - Stanford

New York

  • Memorial Sloan Kettering Cancer Center at Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York

Iowa

  • University of Iowa - Iowa City

Missouri

  • Washington University; Wash Uni. Sch. Of Med - St Louis

New Jersey

  • Memorial Sloan Kettering Bergen - Montvale

Texas

  • Baylor University Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2022-03-22
Est. Completion 2026-09-30
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04980222

The ClinicalTrials.gov registry entry for NCT04980222 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Glofitamab is the first listed.

NCT04980222 reports 18 study locations spanning 7 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT04980222 about?

NCT04980222 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma". This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffus...

What is the current status of trial NCT04980222?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2022-03-22. Estimated completion is 2026-09-30.

What conditions does trial NCT04980222 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT04980222?

The interventions under investigation include: Glofitamab (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Prednisone (DRUG), Tocilizumab (DRUG).

Who is sponsoring clinical trial NCT04980222?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04980222 being conducted?

This trial has 18 study locations across California, Iowa, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.